Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-05-15
2011-11-08
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012100
Reexamination Certificate
active
08053411
ABSTRACT:
The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
REFERENCES:
patent: 5023321 (1991-06-01), Hudson et al.
patent: 5166191 (1992-11-01), Cronin et al.
patent: 5478807 (1995-12-01), Cronin et al.
patent: 5759807 (1998-06-01), Breece et al.
patent: 5811395 (1998-09-01), Schwabe et al.
patent: 5952296 (1999-09-01), Bigazzi
patent: 6211147 (2001-04-01), Unemori
patent: 6723702 (2004-04-01), Conrad et al.
patent: 6780836 (2004-08-01), Unemori
patent: 2004/0192606 (2004-09-01), Unemori
patent: 2004/0266685 (2004-12-01), Conrad et al.
patent: 2005/0113286 (2005-05-01), Schreiner et al.
patent: 2005/0238639 (2005-10-01), Conrad et al.
patent: 2006/0264367 (2006-11-01), Samuel et al.
patent: 2007/0202080 (2007-08-01), Yun et al.
patent: 2008/0077025 (2008-03-01), Delgado-Herrera et al.
patent: WO-93/03755 (1993-03-01), None
patent: 02/40500 (2002-05-01), None
patent: WO-02/40500 (2002-05-01), None
patent: WO-2009/007848 (2009-01-01), None
patent: WO-2009/140657 (2009-11-01), None
Dschietzig et al, The FASEB Journal. 2001; vol. 15, pp. 2187-2195.
McAlister et al, Circulation, 2004, vol. 109, pp. 1004-1009.
Francis et al. Cleve Clin J Med 2006, Vo. 73, pp. S8-S13, especially p. S9.
Beltiz et al, reference Rev. Esp Cardiol, 2010, vol. 63 (30), pp. 2494-3302.
Rozanki et al, The Journal of Medicine, 2000, vol. 41, No. 9, pp. 1445-1450.
Moore et al, Academic Emergency Medicine, 2002, vol. 9, pp. 186-193.
“Corthera Closes $23 Million Financing Round,” Corthera, Inc. Press Release (Dec. 20, 2007), 2 pages.
“Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure,” Corthera, Inc. Press Release (Jan. 8, 2008), 1 page.
“Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure,” Corthera, Inc. Press Release (Oct. 1, 2009), 1 page.
“Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure,” Corthera, Inc. Press Release (Nov. 10, 2008), 1 page.
“Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project relaxin for treatment of acute decompensated heart failure,” Corthera, Inc. Press Release (Dec. 23, 2009), 3 pages.
“Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009,” Corthera, Inc. Press Release (May 28, 2008), 1 page.
“Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session,” Corthera, Inc. Press Release (Mar. 23, 2008), 1 page.
“Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure,” Corthera, Inc. Press Release (Mar. 29, 2008), 2 pages.
“Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008,” Corthera, Inc. Press Release (Nov. 3, 2008), 1 page.
ADHERE Scientific Advisory Committee (2006)Acute Decompensated Heart Failure National Registry(ADHERE)Core Module Q1 2006, Scios, Inc. 53 pages.
Albert et al. (2004). “Evidence-based practice for acute decompensated heart failure,”Critical Care Nurse24(6):14-29.
Allen and O'Connor (2007). “Management of acute decompensated heart failure,”CMAJ176(6):797-805.
Balion et al. (2008). “Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP,”Clinical Biochemistry, 41:231-239.
Bani et al. (1997). “Relaxin counteracts asthma-like reaction induced by inhaled antigen in sensitized guinea pigs,”Endocrinology, 138:1909-1915.
Bathgate et al. (2005). “Receptors for Relaxin Family Peptides,”Ann NY Acad Sci1041:61-76.
Bullesbach et al. (1991). “Total synthesis of human relaxin nd human relaxin derivative by solid-phase peptide synthesis and site-directed chain combination,”The Journal of Biological Chemistry266(17):10754-10761.
Chen et al. (2005) “Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species,”The Journal of Pharmacology and Experimental Therapeutics312(1):83-95.
Conrad & Novak. (2004). “Emerging role of relaxin in renal and cardiovascular Function,”Am J Physiol Integr Comp Physiol287:R250-R261.
Conrad et al. (2004) “Relaxin modifies systemic arterial resistance and compliance in conscious nonpregnant rats,”Endocrinology, 145: 3289-3296.
Cotter et al. (2008). “The pathophysiology of acute heart failure—is it all about fluid accumulation?”American Heart Journal155(1):9-18.
Debrah et al. (2005) “Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response,”J Appl Physiol98: 1013-1020.
Debrah et al. (2005) “Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats,”Hypertension46: 745-750.
Debrah et al. (2006) “Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats,”Endocrinology147: 5126-5131.
Dschietzig et al. (2001). “The pregnancy hormone relaxin is a player in human heart failure,”FASEB Journal15:2187-2195.
Dschietzig et al. (2007) “A pilot safety and dose-finding trial of intravenous recombinant human Relaxin (rhRlx) in compensated congestive heart failure,”Eur Heart J28(abstract supplement): 387.
Dschietzig et al. (2009) “Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial,”J Cardiac Fail, 15: 182-190.
Dschietzig et al. (2009). “First clinical experience with intravenous recombinant human relaxin in compensated heart failure,”Ann NY Acad Sci1160(1):387-392.
Fisher et al. (2003) “N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure,”Heart, 89: 879-881.
Francis (2006). “Acute decompensate heart failure: The cardiorenal syndrome,”Cleveland Clinic Journal of Medicine73(2):1-13.
Garibay-Tupas et al. (2004). “Regulation of the human relaxin genes H1 and H2 by steroid hormones,”Molecular and Cellular Endocrinology219:115-125.
Gheorghiade and Filippatos (2005) “Reassessing treatment of acute heart failure syndromes,”Eur Heart J Supplements, 7(Suppl.B): B13-B19.
Gheorghiade and Zannad (2005) “Modern management of acute heart failure syndromes,”Eur Heart J Supplements, 7(Suppl.B): B3-B7.
Gheorghiade et al. (2006). “Systolic blood pressure ad admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure,”JAMA296: 2217-2226.
Heart Failure Society of America (2006)Pocket Guide: HFSA Comprehensive Heart Failure Practice GuidelineHFSA, St. Paul, MN, pp. 1-95.
Hernandez and Granger (2009) “Advancing care for acute heart failure—no time to relax,”Lancet373: 1401-2. (Epub Mar. 28, 2009).
Heywood (2004). “The cardiorenal syndrome: lessons from the ADHERE database and treatment options,”Heart Fail Rev9:195-201.
Hunt et al. (2005) “ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,”Circulation112(12): e154-235.
Jessup et al. (20
Cotter Gad
Stewart Dennis R.
Teichman Sam L.
Unemori Elaine
Whitehouse Martha Jo
Bunner Bridget E
Corthera, Inc.
Hamud Fozia
Matovcik Lisa
LandOfFree
Method of treating dyspnea associated with acute heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating dyspnea associated with acute heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating dyspnea associated with acute heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255366